Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Oxford BioMedica plc. (8/17/17). "Press Release: Interim Results for the Six Months Ended 30 June 2017". Oxford.

Organisations Organisation Oxford BioMedica plc (LSE: OXB)
  Group Oxford BioMedica (Group)
  Organisation 2 Innovate UK
  Group United Kingdom (GB) (govt)
Products Product LentiVector® technology
  Product 2 tisagenlecleucel-T (CTL019)
  Index term 2 Novartis–Oxford BioMedica: lentiviral vector technology, 201703 supply existent OBM sole producer of lentiviral vector expressing CTL019
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Nolan, Peter (Oxford BioMedica 200507)
     


   
Record changed: 2017-08-24

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Oxford BioMedica (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top